Despite there now being a variety of promising immunotherapies for bladder cancer, a large proportion of patients dont respond to these. Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Andrea Apolo, MD, of the National Cancer Institute, Bethesda, MD, discusses this issue.
Unmet needs in bladder cancer in the immunotherapy era
